Hypertension in diabetes mellitus

C. Arauz-Pacheco, Philip Raskin

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Hypertension should be detected and treated early in diabetic patients. It has a marked contribution to the morbidity and mortality of diabetic individuals due to both atherosclerosis and microvascular disease. Antihypertensive treatment is an effective tool in slowing the progression of early and advanced diabetic nephropathy. Prospective studies addressing the effects of antihypertensive regimens on the incidence of CHF, stroke, and coronary artery disease in the diabetic population are not available. We assume that the beneficial effects of therapy apply to both diabetic and nondiabetic subjects. Glycemic control and the lipid profile are major concerns when selecting an antihypertensive drug. Because hyperinsulinemia and insulin resistance have been advocated as hypertensive and atherosclerotic risk factors, the effects of antihypertensive drugs on insulin action and plasma insulin levels may also become an important element in the selection of an antihypertensive agent. ACE inhibitors, calcium channel blockers, and alpha-adrenergic blockers probably offer the most favorable metabolic profile when compared with diuretics and beta-blockers and should be used as the initial drugs in most clinical settings.

Original languageEnglish (US)
Pages (from-to)401-423
Number of pages23
JournalEndocrinology and Metabolism Clinics of North America
Volume25
Issue number2
DOIs
StatePublished - 1996

Fingerprint

Medical problems
Antihypertensive Agents
Diabetes Mellitus
Hypertension
Insulin
Adrenergic alpha-Antagonists
Metabolome
Calcium Channel Blockers
Hyperinsulinism
Diabetic Nephropathies
Angiotensin-Converting Enzyme Inhibitors
Diuretics
Insulin Resistance
Coronary Artery Disease
Atherosclerosis
Stroke
Prospective Studies
Morbidity
Lipids
Plasmas

ASJC Scopus subject areas

  • Endocrinology
  • Biochemistry

Cite this

Hypertension in diabetes mellitus. / Arauz-Pacheco, C.; Raskin, Philip.

In: Endocrinology and Metabolism Clinics of North America, Vol. 25, No. 2, 1996, p. 401-423.

Research output: Contribution to journalArticle

@article{f6483e2ffe454259a4a08e01f83e363f,
title = "Hypertension in diabetes mellitus",
abstract = "Hypertension should be detected and treated early in diabetic patients. It has a marked contribution to the morbidity and mortality of diabetic individuals due to both atherosclerosis and microvascular disease. Antihypertensive treatment is an effective tool in slowing the progression of early and advanced diabetic nephropathy. Prospective studies addressing the effects of antihypertensive regimens on the incidence of CHF, stroke, and coronary artery disease in the diabetic population are not available. We assume that the beneficial effects of therapy apply to both diabetic and nondiabetic subjects. Glycemic control and the lipid profile are major concerns when selecting an antihypertensive drug. Because hyperinsulinemia and insulin resistance have been advocated as hypertensive and atherosclerotic risk factors, the effects of antihypertensive drugs on insulin action and plasma insulin levels may also become an important element in the selection of an antihypertensive agent. ACE inhibitors, calcium channel blockers, and alpha-adrenergic blockers probably offer the most favorable metabolic profile when compared with diuretics and beta-blockers and should be used as the initial drugs in most clinical settings.",
author = "C. Arauz-Pacheco and Philip Raskin",
year = "1996",
doi = "10.1016/S0889-8529(05)70330-3",
language = "English (US)",
volume = "25",
pages = "401--423",
journal = "Endocrinology and Metabolism Clinics of North America",
issn = "0889-8529",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Hypertension in diabetes mellitus

AU - Arauz-Pacheco, C.

AU - Raskin, Philip

PY - 1996

Y1 - 1996

N2 - Hypertension should be detected and treated early in diabetic patients. It has a marked contribution to the morbidity and mortality of diabetic individuals due to both atherosclerosis and microvascular disease. Antihypertensive treatment is an effective tool in slowing the progression of early and advanced diabetic nephropathy. Prospective studies addressing the effects of antihypertensive regimens on the incidence of CHF, stroke, and coronary artery disease in the diabetic population are not available. We assume that the beneficial effects of therapy apply to both diabetic and nondiabetic subjects. Glycemic control and the lipid profile are major concerns when selecting an antihypertensive drug. Because hyperinsulinemia and insulin resistance have been advocated as hypertensive and atherosclerotic risk factors, the effects of antihypertensive drugs on insulin action and plasma insulin levels may also become an important element in the selection of an antihypertensive agent. ACE inhibitors, calcium channel blockers, and alpha-adrenergic blockers probably offer the most favorable metabolic profile when compared with diuretics and beta-blockers and should be used as the initial drugs in most clinical settings.

AB - Hypertension should be detected and treated early in diabetic patients. It has a marked contribution to the morbidity and mortality of diabetic individuals due to both atherosclerosis and microvascular disease. Antihypertensive treatment is an effective tool in slowing the progression of early and advanced diabetic nephropathy. Prospective studies addressing the effects of antihypertensive regimens on the incidence of CHF, stroke, and coronary artery disease in the diabetic population are not available. We assume that the beneficial effects of therapy apply to both diabetic and nondiabetic subjects. Glycemic control and the lipid profile are major concerns when selecting an antihypertensive drug. Because hyperinsulinemia and insulin resistance have been advocated as hypertensive and atherosclerotic risk factors, the effects of antihypertensive drugs on insulin action and plasma insulin levels may also become an important element in the selection of an antihypertensive agent. ACE inhibitors, calcium channel blockers, and alpha-adrenergic blockers probably offer the most favorable metabolic profile when compared with diuretics and beta-blockers and should be used as the initial drugs in most clinical settings.

UR - http://www.scopus.com/inward/record.url?scp=0029976578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029976578&partnerID=8YFLogxK

U2 - 10.1016/S0889-8529(05)70330-3

DO - 10.1016/S0889-8529(05)70330-3

M3 - Article

C2 - 8799706

AN - SCOPUS:0029976578

VL - 25

SP - 401

EP - 423

JO - Endocrinology and Metabolism Clinics of North America

JF - Endocrinology and Metabolism Clinics of North America

SN - 0889-8529

IS - 2

ER -